REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 204 filers reported holding REATA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,271,078 | +280.1% | 41,890 | +238.9% | 0.01% | +250.0% |
| Q1 2023 | $1,123,797 | +38.0% | 12,361 | -42.3% | 0.00% | 0.0% |
| Q4 2022 | $814,283 | +9.2% | 21,426 | +195.9% | 0.00% | 0.0% |
| Q3 2021 | $746,000 | -30.3% | 7,241 | -1.3% | 0.00% | 0.0% |
| Q2 2021 | $1,071,000 | +28.3% | 7,336 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $835,000 | -13.3% | 7,577 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $963,000 | +110.7% | 7,908 | +67.8% | 0.00% | +100.0% |
| Q3 2020 | $457,000 | -40.4% | 4,714 | -4.1% | 0.00% | -50.0% |
| Q2 2020 | $767,000 | -6.6% | 4,918 | -13.7% | 0.00% | -33.3% |
| Q1 2020 | $821,000 | -15.4% | 5,702 | +20.2% | 0.00% | 0.0% |
| Q4 2019 | $971,000 | +96.6% | 4,742 | -10.1% | 0.00% | +50.0% |
| Q2 2019 | $494,000 | -22.2% | 5,275 | -29.4% | 0.00% | 0.0% |
| Q1 2019 | $635,000 | +30.7% | 7,467 | -13.8% | 0.00% | 0.0% |
| Q4 2018 | $486,000 | – | 8,665 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |